Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations
The antiviral treatment of chronic hepatitis B is limited by the selection of antiviral resistance mutations. Primary resistance to lamivudine occurs at rtM2041/V in the C Domain of the polymerase. Recently, resistance to adefovir has also been described in the D Domain at rtN236T. The treatment of...
Gespeichert in:
| Veröffentlicht in: | Antiviral therapy 2004-04, Vol.9 (2), p.149-160 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 160 |
|---|---|
| container_issue | 2 |
| container_start_page | 149 |
| container_title | Antiviral therapy |
| container_volume | 9 |
| creator | BARTHOLOMEUSZ, Angeline TEHAN, Benjamin G CHALMERS, David K |
| description | The antiviral treatment of chronic hepatitis B is limited by the selection of antiviral resistance mutations. Primary resistance to lamivudine occurs at rtM2041/V in the C Domain of the polymerase. Recently, resistance to adefovir has also been described in the D Domain at rtN236T. The treatment of patients with resistant virus without complete suppression can lead to the further selection of compensatory mutations. Thus, to gain an understanding of the hepatitis B virus (HBV) polymerase and also mutations associated with resistance, a three-dimensional model of the HBV reverse transcriptase core region based on homology with human immunodeficiency virus (HIV) was created. A comparative analysis of the HIV polymerase and the model of HBV polymerase was performed. In addition, the antiviral resistance mutations including potential compensatory mutations were mapped to determine their effect on the HBV polymerase model, especially in the nucleotide binding site. |
| doi_str_mv | 10.1177/135965350400900203 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71906825</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71906825</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-738e9442af7008d4e2e88cac65db7cf47be13bcd560bed468ba70a95344bf3a23</originalsourceid><addsrcrecordid>eNpl0MtKAzEUBuAgiq3VF3Ah2ejK0VwnmaUWtYWKG-12OJPJYGQuNZkR-vamdkDBVTjhO_-BH6FzSm4oVeqWcpmlkksiCMkIYYQfoCmLU8KI1IdougPJTkzQSQgfkejojtGESspFjJii53nXbMC70LUBdxXu3y1e3K8xtCVeLNd409XbxnoI9vrnD9refTkPNfY2uNBDayxuhh56FxNO0VEFdbBn4ztDb48Pr_NFsnp5Ws7vVokRPOsTxbXNhGBQKUJ0KSyzWhswqSwLZSqhCkt5YUqZksKWItUFKAKZ5EIUFQfGZ-hqn7vx3edgQ583Lhhb19Dabgi5ohlJNZMRsj00vgvB2yrfeNeA3-aU5LsS8_8lxqWLMX0oGlv-roytRXA5AggG6srHFlz441S8zVL-DcpqeOk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71906825</pqid></control><display><type>article</type><title>Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations</title><source>MEDLINE</source><source>Sage Journals GOLD Open Access 2024</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>BARTHOLOMEUSZ, Angeline ; TEHAN, Benjamin G ; CHALMERS, David K</creator><creatorcontrib>BARTHOLOMEUSZ, Angeline ; TEHAN, Benjamin G ; CHALMERS, David K</creatorcontrib><description>The antiviral treatment of chronic hepatitis B is limited by the selection of antiviral resistance mutations. Primary resistance to lamivudine occurs at rtM2041/V in the C Domain of the polymerase. Recently, resistance to adefovir has also been described in the D Domain at rtN236T. The treatment of patients with resistant virus without complete suppression can lead to the further selection of compensatory mutations. Thus, to gain an understanding of the hepatitis B virus (HBV) polymerase and also mutations associated with resistance, a three-dimensional model of the HBV reverse transcriptase core region based on homology with human immunodeficiency virus (HIV) was created. A comparative analysis of the HIV polymerase and the model of HBV polymerase was performed. In addition, the antiviral resistance mutations including potential compensatory mutations were mapped to determine their effect on the HBV polymerase model, especially in the nucleotide binding site.</description><identifier>ISSN: 1359-6535</identifier><identifier>EISSN: 2040-2058</identifier><identifier>DOI: 10.1177/135965350400900203</identifier><identifier>PMID: 15134177</identifier><language>eng</language><publisher>London: International Medical Press</publisher><subject>Amino Acid Sequence ; Animals ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Antiviral Agents - pharmacology ; Base Sequence ; Biological and medical sciences ; Drug Resistance, Viral ; Hepatitis B virus - drug effects ; Hepatitis B virus - enzymology ; Hepatitis B virus - genetics ; Hepatitis B, Chronic - virology ; HIV Reverse Transcriptase - chemistry ; HIV Reverse Transcriptase - genetics ; Humans ; Medical sciences ; Models, Molecular ; Molecular Sequence Data ; Mutation ; Pharmacology. Drug treatments ; RNA-Directed DNA Polymerase - chemistry ; RNA-Directed DNA Polymerase - genetics</subject><ispartof>Antiviral therapy, 2004-04, Vol.9 (2), p.149-160</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-738e9442af7008d4e2e88cac65db7cf47be13bcd560bed468ba70a95344bf3a23</citedby><cites>FETCH-LOGICAL-c439t-738e9442af7008d4e2e88cac65db7cf47be13bcd560bed468ba70a95344bf3a23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15782526$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15134177$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BARTHOLOMEUSZ, Angeline</creatorcontrib><creatorcontrib>TEHAN, Benjamin G</creatorcontrib><creatorcontrib>CHALMERS, David K</creatorcontrib><title>Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations</title><title>Antiviral therapy</title><addtitle>Antivir Ther</addtitle><description>The antiviral treatment of chronic hepatitis B is limited by the selection of antiviral resistance mutations. Primary resistance to lamivudine occurs at rtM2041/V in the C Domain of the polymerase. Recently, resistance to adefovir has also been described in the D Domain at rtN236T. The treatment of patients with resistant virus without complete suppression can lead to the further selection of compensatory mutations. Thus, to gain an understanding of the hepatitis B virus (HBV) polymerase and also mutations associated with resistance, a three-dimensional model of the HBV reverse transcriptase core region based on homology with human immunodeficiency virus (HIV) was created. A comparative analysis of the HIV polymerase and the model of HBV polymerase was performed. In addition, the antiviral resistance mutations including potential compensatory mutations were mapped to determine their effect on the HBV polymerase model, especially in the nucleotide binding site.</description><subject>Amino Acid Sequence</subject><subject>Animals</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - pharmacology</subject><subject>Base Sequence</subject><subject>Biological and medical sciences</subject><subject>Drug Resistance, Viral</subject><subject>Hepatitis B virus - drug effects</subject><subject>Hepatitis B virus - enzymology</subject><subject>Hepatitis B virus - genetics</subject><subject>Hepatitis B, Chronic - virology</subject><subject>HIV Reverse Transcriptase - chemistry</subject><subject>HIV Reverse Transcriptase - genetics</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Models, Molecular</subject><subject>Molecular Sequence Data</subject><subject>Mutation</subject><subject>Pharmacology. Drug treatments</subject><subject>RNA-Directed DNA Polymerase - chemistry</subject><subject>RNA-Directed DNA Polymerase - genetics</subject><issn>1359-6535</issn><issn>2040-2058</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpl0MtKAzEUBuAgiq3VF3Ah2ejK0VwnmaUWtYWKG-12OJPJYGQuNZkR-vamdkDBVTjhO_-BH6FzSm4oVeqWcpmlkksiCMkIYYQfoCmLU8KI1IdougPJTkzQSQgfkejojtGESspFjJii53nXbMC70LUBdxXu3y1e3K8xtCVeLNd409XbxnoI9vrnD9refTkPNfY2uNBDayxuhh56FxNO0VEFdbBn4ztDb48Pr_NFsnp5Ws7vVokRPOsTxbXNhGBQKUJ0KSyzWhswqSwLZSqhCkt5YUqZksKWItUFKAKZ5EIUFQfGZ-hqn7vx3edgQ583Lhhb19Dabgi5ohlJNZMRsj00vgvB2yrfeNeA3-aU5LsS8_8lxqWLMX0oGlv-roytRXA5AggG6srHFlz441S8zVL-DcpqeOk</recordid><startdate>20040401</startdate><enddate>20040401</enddate><creator>BARTHOLOMEUSZ, Angeline</creator><creator>TEHAN, Benjamin G</creator><creator>CHALMERS, David K</creator><general>International Medical Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040401</creationdate><title>Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations</title><author>BARTHOLOMEUSZ, Angeline ; TEHAN, Benjamin G ; CHALMERS, David K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-738e9442af7008d4e2e88cac65db7cf47be13bcd560bed468ba70a95344bf3a23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Amino Acid Sequence</topic><topic>Animals</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - pharmacology</topic><topic>Base Sequence</topic><topic>Biological and medical sciences</topic><topic>Drug Resistance, Viral</topic><topic>Hepatitis B virus - drug effects</topic><topic>Hepatitis B virus - enzymology</topic><topic>Hepatitis B virus - genetics</topic><topic>Hepatitis B, Chronic - virology</topic><topic>HIV Reverse Transcriptase - chemistry</topic><topic>HIV Reverse Transcriptase - genetics</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Models, Molecular</topic><topic>Molecular Sequence Data</topic><topic>Mutation</topic><topic>Pharmacology. Drug treatments</topic><topic>RNA-Directed DNA Polymerase - chemistry</topic><topic>RNA-Directed DNA Polymerase - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BARTHOLOMEUSZ, Angeline</creatorcontrib><creatorcontrib>TEHAN, Benjamin G</creatorcontrib><creatorcontrib>CHALMERS, David K</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Antiviral therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BARTHOLOMEUSZ, Angeline</au><au>TEHAN, Benjamin G</au><au>CHALMERS, David K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations</atitle><jtitle>Antiviral therapy</jtitle><addtitle>Antivir Ther</addtitle><date>2004-04-01</date><risdate>2004</risdate><volume>9</volume><issue>2</issue><spage>149</spage><epage>160</epage><pages>149-160</pages><issn>1359-6535</issn><eissn>2040-2058</eissn><abstract>The antiviral treatment of chronic hepatitis B is limited by the selection of antiviral resistance mutations. Primary resistance to lamivudine occurs at rtM2041/V in the C Domain of the polymerase. Recently, resistance to adefovir has also been described in the D Domain at rtN236T. The treatment of patients with resistant virus without complete suppression can lead to the further selection of compensatory mutations. Thus, to gain an understanding of the hepatitis B virus (HBV) polymerase and also mutations associated with resistance, a three-dimensional model of the HBV reverse transcriptase core region based on homology with human immunodeficiency virus (HIV) was created. A comparative analysis of the HIV polymerase and the model of HBV polymerase was performed. In addition, the antiviral resistance mutations including potential compensatory mutations were mapped to determine their effect on the HBV polymerase model, especially in the nucleotide binding site.</abstract><cop>London</cop><pub>International Medical Press</pub><pmid>15134177</pmid><doi>10.1177/135965350400900203</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1359-6535 |
| ispartof | Antiviral therapy, 2004-04, Vol.9 (2), p.149-160 |
| issn | 1359-6535 2040-2058 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71906825 |
| source | MEDLINE; Sage Journals GOLD Open Access 2024; EZB-FREE-00999 freely available EZB journals |
| subjects | Amino Acid Sequence Animals Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - pharmacology Base Sequence Biological and medical sciences Drug Resistance, Viral Hepatitis B virus - drug effects Hepatitis B virus - enzymology Hepatitis B virus - genetics Hepatitis B, Chronic - virology HIV Reverse Transcriptase - chemistry HIV Reverse Transcriptase - genetics Humans Medical sciences Models, Molecular Molecular Sequence Data Mutation Pharmacology. Drug treatments RNA-Directed DNA Polymerase - chemistry RNA-Directed DNA Polymerase - genetics |
| title | Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T00%3A52%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparisons%20of%20the%20HBV%20and%20HIV%20polymerase,%20and%20antiviral%20resistance%20mutations&rft.jtitle=Antiviral%20therapy&rft.au=BARTHOLOMEUSZ,%20Angeline&rft.date=2004-04-01&rft.volume=9&rft.issue=2&rft.spage=149&rft.epage=160&rft.pages=149-160&rft.issn=1359-6535&rft.eissn=2040-2058&rft_id=info:doi/10.1177/135965350400900203&rft_dat=%3Cproquest_cross%3E71906825%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71906825&rft_id=info:pmid/15134177&rfr_iscdi=true |